Angeion's Sentinel ICDs (implantable cardioverter defibrillators) with extended lifetime:
This article was originally published in Clinica
Angeion has received premarket approval from the FDA for its Sentinel series of implantable cardioverter defibrillators. The series consists of ICD models 2000, 2010, 2011 and 2012, the Angeflex lead system, an ICD programming system and the external defibrillation test system. The Minneapolis, Minnesota-based company says a new dual battery system gives the products an extended lifetime of 10 years.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.